Intel Labs and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) have completed a joint research study using federated learning – a distributed machine learning (ML) artificial intelligence (AI) approach – to help international healthcare and research institutions identify malignant brain tumours.
The largest medical federated learning study to date with an unprecedented global dataset examined from 71 institutions across six continents, the project demonstrated the ability to improve brain tumour detection by 33%.
“Federated learning has tremendous potential across numerous domains, particularly within healthcare, as shown by our research with Penn Medicine,” says Jason Martin, principal engineer at Intel Labs. “Its ability to protect sensitive information and data opens the door for future studies and collaboration, especially in cases where datasets would otherwise be inaccessible.
“Our work with Penn Medicine has the potential to positively impact patients across the globe and we look forward to continuing to explore the promise of federated learning.”
Data accessibility has long been an issue in healthcare because of state and national data privacy laws, including the Health Insurance Portability and Accountability Act (HIPAA). Because of this, medical research and data sharing at scale have been almost impossible to achieve without compromising patient health information.
Intel’s federated learning hardware and software comply with data privacy concerns and preserve data integrity, privacy and security through confidential computing.
The Penn Medicine-Intel result was accomplished by processing high volumes of data in a decentralised system using Intel federated learning technology paired with Intel Software Guard Extensions (SGX), which removes data-sharing barriers that have historically prevented collaboration on similar cancer and disease research.
The system addresses numerous data privacy concerns by keeping raw data inside the data holders’ compute infrastructure and only allowing model updates computed from that data to be sent to a central server or aggregator, not the data itself.
“All of the computing power in the world can’t do much without enough data to analyse,” says Rob Enderle, principal analyst at Enderle Group. “This inability to analyse data that has already been captured has significantly delayed the massive medical breakthroughs AI has promised. This federated learning study showcases a viable path for AI to advance and achieve its potential as the most powerful tool to fight our most difficult ailments.”
Senior author Dr Spyridon Bakas, assistant professor of Pathology & Laboratory Medicine and Radiology at the Perelman School of Medicine, comments: “In this study, federated learning shows its potential as a paradigm shift in securing multi-institutional collaborations by enabling access to the largest and most diverse dataset of glioblastoma patients ever considered in the literature, while all data are retained within each institution at all times.
“The more data we can feed into machine learning models, the more accurate they become, which in turn can improve our ability to understand and treat even rare diseases, such as glioblastoma.”
To advance the treatment of diseases, researchers must access large amounts of medical data – in most cases, datasets that exceed the threshold that one facility can produce. The research demonstrates the effectiveness of federated learning at scale and the potential benefits the healthcare industry can realise when multisite data silos are unlocked. Benefits include early detection of disease, which could improve quality of life or increase a patient’s lifespan.
The results of the Penn Medicine-Intel Labs research were published in the peer-reviewed journal, Nature Communications.
Background
In 2020, Intel and Penn Medicine announced the agreement to co-operate and use federated learning to improve tumor detection and improve treatment outcomes of a rare form of cancer called glioblastoma (GBM), the most common and fatal adult brain tumour with a median survival of just 14 months after standard treatment.
While treatment options have expanded over the past 20 years, there has not been an improvement in overall survival rates.
The research was funded by the Informatics Technology for Cancer Research programme out of the National Cancer Institute of the National Institutes of Health.
Penn Medicine and 71 international healthcare/research institutions used Intel’s federated learning hardware and software to improve the detection of rare cancer boundaries. A new AI software platform called Federated Tumour Segmentation (FeTS) was used by radiologists to determine the boundary of a tumour and improve the identification of the “operable region” of tumours or “tumour core”.
Radiologists annotated their data and used open federated learning (OpenFL), an open source framework for training machine learning algorithms, to run the federated training. The platform was trained on 3,7-million images from 6 314 GBM patients across six continents, the largest brain tumour dataset to date.
Through this project, Intel Labs and Penn Medicine have created a proof of concept for using federated learning to gain knowledge from data. The solution can significantly affect healthcare and other study areas, particularly among other types of cancer research.
Specifically, Intel developed the OpenFL open source project to enable customers to adopt real-world cross-silo federated learning and confidently deploy it on Intel SGX.
In addition, the novel FeTS initiative was established as a collaborative network to provide a platform for ongoing development and to encourage collaboration with the FeTS platform and Intel’s OpenFL open source toolkit, both available on GitHub.